A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease.

A three-molecular-window approach for (1)H NMR spectroscopy of serum is presented to obtain specific molecular data on lipoproteins, various low-molecular-weight metabolites, and individual lipid molecules together with their degree of (poly)(un)saturation. The multiple data were analysed with self-organising maps, illustrating the strength of the approach as a holistic metabonomics framework in solely data-driven metabolic phenotyping. We studied 180 serum samples of which 30% were related to mild cognitive impairment (MCI), a neuropsychological diagnosis with severely increased risk for Alzheimer's disease (AD). The results underline the association between MCI and the metabolic syndrome (MetS). Additionally, the low relativeamount of omega-3 fatty acids appears more indicative of MCI than low serum omega-3 or polyunsaturated fatty acid concentration as such. The analyses also feature the role of elevated glycoproteins in the risk for AD, supporting the view that coexistence of inflammation and the MetS forms a high risk condition for cognitive decline.

[1]  M. Kivipelto,et al.  Cholesterol as a risk factor for Alzheimer's disease – epidemiological evidence , 2006, Acta neurologica Scandinavica. Supplementum.

[2]  Mika Ala-Korpela,et al.  Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics , 2008, Clinical chemistry and laboratory medicine.

[3]  A. Newman,et al.  The metabolic syndrome, inflammation, and risk of cognitive decline. , 2004, JAMA.

[4]  Julian L Griffin,et al.  Current challenges in metabolomics for diabetes research: a vital functional genomic tool or just a ploy for gaining funding? , 2008, Physiological genomics.

[5]  J. Smit,et al.  Serum inflammatory proteins and cognitive decline in older persons , 2005, Neurology.

[6]  T. Davis,et al.  The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. , 2001, British journal of clinical pharmacology.

[7]  S Mierisová,et al.  MR spectroscopy quantitation: a review of frequency domain methods , 2001, NMR in biomedicine.

[8]  Reino Laatikainen,et al.  Strategies for organic impurity quantification by 1H NMR spectroscopy: Constrained total-line-shape fitting , 2005 .

[9]  C. Lyketsos,et al.  Serum sphingomyelins and ceramides are early predictors of memory impairment , 2010, Neurobiology of Aging.

[10]  Tuomo Hänninen,et al.  Prevalence of mild cognitive impairment: a population‐based study in elderly subjects , 2002, Acta neurologica Scandinavica.

[11]  Aki Vehtari,et al.  A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data , 2007, BMC Bioinformatics.

[12]  M. Ala-Korpela.  Potential role of body fluid 1H NMR metabonomics as a prognostic and diagnostic tool , 2007, Expert review of molecular diagnostics.

[13]  R. Martins,et al.  Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease , 2006, Molecular Psychiatry.

[14]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[15]  M. Zoli,et al.  Plasma amino acid concentrations in patients with amnestic mild cognitive impairment or Alzheimer disease. , 2004, The American journal of clinical nutrition.

[16]  K. Kaski,et al.  1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death , 2008, Molecular systems biology.

[17]  Ian J. Brown,et al.  Human metabolic phenotype diversity and its association with diet and blood pressure , 2008, Nature.

[18]  S. Tayebati,et al.  Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. , 2008, Current medicinal chemistry.

[19]  Hilkka Soininen,et al.  CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI , 2007, Neurobiology of Aging.

[20]  M. Anderson,et al.  NMR lipid profiles of cells, tissues, and body fluids: proton NMR analysis of human erythrocyte lipids. , 1994, Journal of lipid research.

[21]  J. Vion-Dury,et al.  Magnetic resonance spectroscopy of serum and acute-phase proteins revisited: a multiparametric statistical analysis of metabolite variations in inflammatory, infectious and miscellaneous diseases. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[22]  H. Feldman,et al.  Cholesterol in Alzheimer's disease , 2005, The Lancet Neurology.